FindTrial
Sign In

Canagliflozin (JNJ-28431754)

DRUG12 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Janssen Research & Development, LLC

Conditions

Diabetes Mellitus, Non Insulin DependentDiabetes Mellitus, Type 2Diabetes Mellitus, Type IIHealthyObesityRenal Insufficiency

Phase 1

A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of Digoxin in Healthy Volunteers.
CompletedNCT01714206
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy
Start: 2009-06-30End: 2009-09-30Updated: 2012-11-19
A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics and Safety of an Oral Contraceptive in Healthy Volunteers
CompletedNCT01714193
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy
Start: 2008-02-29End: 2008-03-31Updated: 2012-11-19
A Study to Assess the Effects of Cyclosporine on the Pharmacokinetics and Safety of Canagliflozin (JNJ-28431754) in Healthy Volunteers
CompletedNCT01718652
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy
Start: 2011-02-28End: 2011-04-30Updated: 2012-11-27
A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Glyburide in Healthy Volunteers
CompletedNCT01733108
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy
Start: 2008-07-31End: 2008-09-30Updated: 2012-12-12
A Study to Investigate Whether Pharmacokinetic and Pharmacodynamic Interactions Exist Between Metformin and Canagliflozin (JNJ-28431754) in Healthy Volunteers
CompletedNCT01756417
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy
Start: 2007-10-31End: 2007-11-30Updated: 2016-06-29
Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy Obese Volunteers
CompletedNCT01756404
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy
Start: 2007-06-14End: 2007-12-05Updated: 2018-12-13
A Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Volunteers With Varying Degrees of Kidney Function
CompletedNCT01759576
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy, Renal Insufficiency
Start: 2008-03-31End: 2008-11-30Updated: 2013-05-29
A Study to Assess Electrocardiogram Results in Healthy Volunteers Receiving Canagliflozin (JNJ-28431754)
CompletedNCT01787357
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy
Start: 2008-06-30End: 2008-09-30Updated: 2016-06-29
A Study to Assess the Effects of Canagliflozin (JNJ-28431754) on the Pharmacokinetics, Pharmacodynamics, and Safety of Simvastatin in Healthy Volunteers
CompletedNCT01821027
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Healthy
Start: 2008-08-31End: 2008-09-30Updated: 2013-03-29

Phase 2

An Efficacy, Safety, and Tolerability Study of Canagliflozin (JNJ-28431754) in Patients With Type 2 Diabetes
CompletedNCT00642278
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Diabetes Mellitus, Non Insulin Dependent, Diabetes Mellitus, Type II
Start: 2008-04-30End: 2009-01-31Updated: 2013-07-19
A Study of the Safety and Effectiveness of Canagliflozin (JNJ-28431754) in Promoting Weight Loss in Overweight and Obese Patients Who do Not Have Diabetes
CompletedNCT00650806
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Obesity
Start: 2008-05-31End: 2008-09-30Updated: 2013-05-24

Phase 3

CANagliflozin Treatment And Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride
CompletedNCT00968812
Janssen Research & Development, LLCDiabetes Mellitus, Type 2
Start: 2009-09-30End: 2013-01-31Updated: 2017-01-30

Related Papers

Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease.
2019-04-17357 citations
Longer-term safety and tolerability of canagliflozin in patients with type 2 diabetes: a pooled analysis
Current Medical Research and Opinion2016-12-1932 citations
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus living in hot climates
International Journal of Clinical Practice2016-09-0121 citations
A post-hoc analysis of the comparative efficacy of canagliflozin and glimepiride in the attainment of type 2 diabetes-related quality measures.
2016-08-058 citations
Effects of canagliflozin on body weight and body composition in patients with type 2 diabetes over 104 weeks
Postgraduate Medicine2016-03-2265 citations
Simultaneous Reduction in Both HbA1c and Body Weight with Canagliflozin Versus Glimepiride in Patients with Type 2 Diabetes on Metformin.
2016-03-1614 citations
Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from Latin America
Current Medical Research and Opinion2015-11-1810 citations
Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
2015-02-0334 citations
Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies.
2014-02-21112 citations
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
2013-07-12576 citations
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
2012-05-1555 citations